Dr Liz Christie is a Group Leader in the Cancer Evolution and Metastasis Program at the Peter MacCallum Cancer Centre, where her team investigates the evolution of acquired treatment resistance in ovarian and endometrial cancer using multi-omics approaches to analyse patient samples.
Liz completed her PhD in 2013 at the Ludwig Institute for Cancer Research and the University of Melbourne, studying intestinal development in zebrafish and how these processes are recapitulated in cancer.
Liz then joined the Peter MacCallum Cancer for her post doc under the mentorship of Professor David Bowtell, where she led a research program aimed at understanding the genomic mechanisms of acquired drug resistance in ovarian cancer, including examining circulating tumour DNA (ctDNA) as non-invasive biomarker to evaluate resistance. Her work resulted in first author papers in high-impact journals including Nature and Journal of Clinical Oncology, which have received >800 citations.
Liz has also received a number of grants and awards, including the NBCF Joseph F Sambrook Prize for Research Excellence and the Peter Mac Early Career Development Award, and she is currently supported by a VCA Mid Career Research Fellowship.
Early Career Development Award, Peter MacCallum Cancer Centre, 2021
Lea Medal, Highly Commended, Peter MacCallum Cancer Centre, 2019
Accelerating Discovery & Translational Research Award, Peter MacCallum Cancer Centre, 2018
NBCF Joseph F Sambrook Prize for Research Excellence, Familial Aspects of Cancer Research & Practice Meeting, 2018
Joseph F. Sambrook Prize for Research Excellence, Peter MacCallum Cancer Centre, 2017